No doubt your days will be packed while you’re at San Francisco’s Moscone Center, weaving through the crowds as you make your way to various sessions and presentations at ENDO 2025. Here are just a few highlights – among hundreds – that might appeal to you.
Saturday July 12
Stalk Lesions of the Pituitary Gland 9:45 AM
While endocrinologists are more familiar with the evaluation of pituitary incidentaloma, patients with lesions of the pituitary stalk present a different set of differential diagnoses and diagnostic strategies that may be unfamiliar to many endocrinologists. Lesions of the stalk may represent neoplastic, inflammatory or infiltrative processes. Here we present review of causes of pituitary stalk lesions as well as case based discussion highlighting strategies for imaging and laboratory evaluation.
Testosterone: New Research Informing Clinical Practice 4:30 PM
This session will feature expert discussion of 1. Recent findings from observational studies of testosterone and key health outcomes in men, 2. Results from recent major testosterone randomised clinical trials, and 3. Implications of these data for clinical management of men with and without disorders causing hypogonadism.
Sunday July 13
SGLT-2 Inhibitor Therapy in Type 2 Diabetes: Pitfalls and Advantages 9:30 AM
SGLT-2 inhibitors use for diabetes management in primary care and subspecialty clinics continues to grow though their prescription remains underutilized. One of the obstacles precluding wider use of these agents is providers` fear of causing more likely immediate side effects despite known improvements in morbidity and mortality that are accrued with chronic SGLT-2i prescription. A significant barrier is development of diabetic ketoacidosis (DKA). Fortunately, there is a growing body of knowledge of strategies that may help avoid DKA. Further, a novel post-marketing observation reported by several groups over last years including our group shows that SGLT-2i can cause erythrocytosis which can potentially negatively impact CV health. This novel phenomenon is particularly evident in the setting of combined prescription of SGLT-2i and testosterone replacement. This session will summarize newest developments in the field and allow practitioners to become more confident in using SGLT-2i.
Maximizing LinkedIn: Strategies to Achieve Your Professional Goals 1:30 PM
Experts will describe best practices to improve LinkedIn profile views and offer an inside look at how non-academics use LinkedIn to find experts. Panelists will share their personal suggestions based on their experiences with LinkedIn.
Monday July 14
Plenary: Innovative Approaches in Obesity Care: From Molecules to Society 8:00 AM
This plenary presentation will delve into the transformative landscape of obesity care, emphasizing the integration of innovative policies, dietary strategies, and pharmacological advancements. We will explore how these elements collectively reshape treatment paradigms across different life stages, from childhood through adulthood. By examining recent policy initiatives, we will highlight their impact on public health frameworks and access to care. Furthermore, we will discuss the latest dietary interventions that align with personalized medicine approaches, promoting sustainable lifestyle changes. The session will also cover cutting-edge drug innovations that offer new hope for effective weight management. Attendees will gain insights into how these evolving strategies can be implemented in clinical practice to improve patient outcomes and reduce the burden of obesity. This comprehensive overview aims to equip healthcare professionals with the knowledge to advocate for and implement holistic, evidence-based approaches in obesity care.
Clinical Pearls from JCEM Case Reports 9:30 AM
This 45-minute session includes presentations from the authors of 3 unique and challenging case reports published in JCEM Case Reports. After each presentation, a content expert will share their insights and clinical pearls. Attendees will have the opportunity to ask questions of the case presenters and the content experts. The session will be co-chaired by the Editor-in-Chief: William F. Young, Jr., MD and the Deputy Editor: Adina Turcu, MD, MS.
Tuesday July 15
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline 9:00 AM
Using a case-based format, this session will provide an overview of the recommendations from the 2025 Endocrine Society guideline on the diagnosis and treatment of primary aldosteronism. Guideline methodology will be reviewed, and clinical cases will be presented highlighting the top prioritized clinical questions that underpinned the guideline recommendations. Bring your questions for the panel and learn what the experts have to say about this important topic.
A ‘Bone-Anza’ of Recent Advances in Parathyroid Disease 9:00 AM
Therapies for parathyroid diseases have evolved greatly over the past 10 years, including the recent development and approval of PTH replacement therapies for hypoparathyroidism. This translational session reviews recent advances in the development of novel therapies that target the PTH receptor, discuss the role of JAK inhibitors as a potential therapeutic strategy for autoimmune hypoparathyroidism in APS1, and current clinical strategies for the management of parathyroid diseases.
These sessions are just a tiny fraction of the dozens of options available to attendees that cover a vast range of topics in patient treatment outcomes, basic science, and clinical research. Check out more sessions!
Loading ...